Hereditary Angioedema (HAE) Therapeutics Market - Top Companies and Manufacturers

Companies Dominating the Hereditary Angioedema Treatment Landscape

The hereditary angioedema treatment market is dominated is dominated by several key companies, significantly shaping the landscape of innovative treatments. These companies focus on both acute and prophylactic treatments. In September 2021, Cycle Pharmaceuticals announced the launch of SAJAZIR Injection, a new treatment option for patients affected by Hereditary Angioedema. The treatment has been approved by the US Food and Drug Administration (FDA). Competitive dynamics in the hereditary angioedema treatment market have intensified in the last few years. Companies are seeking to differentiate their products through improved efficacy, safety, and ease of use. Some of these prominent companies are:

Attune Pharmaceuticals
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
BioCryst Pharmaceuticals, Inc.
Biomarin
CSL Behring LLC
Intellia Therapeutics
Ionis Pharmaceuticals
KalVista Pharmaceuticals, Inc.
Pharming Healthcare, Inc.
Pharvaris

Browse Key Market Insights with Data Illustration:

Hereditary Angioedema Treatment Market Size, Growth Report 2037

In the News

In January 2024, Ionis Pharmaceuticals, Inc. announced positive results for the Phase 3 OASIS-HAE study of donidalorsen in people with hereditary angioedema
In March 2023, Intellia Therapeutics received FDA clearance for an Investigational New Drug (IND) application for NTLA-2002. It is an in vivo genome editing candidate designed to inactivate the target gene and prevent HAE attacks after a single-dose treatment.
In November 2022, BioCryst Pharmaceuticals, Inc. received marketing authorization from the Israeli Ministry of Health for oral, once-daily ORLADEYO to prevent HAE attacks.
In July 2021, Orchard Therapeutics and Pharming Group N.V. announced a strategic collaboration to research, develop, manufacture, and commercialize OTL-105, for the treatment of hereditary angioedema.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the hereditary angioedema treatment market was over USD 5.3 billion.

The market size for the hereditary angioedema treatment market is projected to reach USD 15.7 billion by the end of 2037 expanding at a CAGR of 9.5% during the forecast period i.e., between 2025-2037.

The major players in the market are BioCryst Pharmaceuticals, Inc., Biomarin, CSL Behring LLC, and others.

In terms of age group segment, the adults segment is anticipated to garner the largest market share by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 50.5% by the end of 2037 and provide more business opportunities in the future.

Hereditary Angioedema (HAE) Therapeutics Market - Top Companies and Manufacturers

Companies Dominating the Hereditary Angioedema Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the hereditary angioedema treatment market?

What is the outlook for the hereditary angioedema treatment market?

Who are the major players dominating the hereditary angioedema treatment market?

Which age group segment will capture the significant market share for the hereditary angioedema treatment market by 2037?

Which region will provide more business opportunities for the growth of the hereditary angioedema treatment market in the future?